Overview

Continued Access to RXDX-105

Status:
Completed

Trial end date:
2020-09-30

Target enrollment:

Participant gender:

Summary

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

Agerafenib